Jin Ooi

Partner @Kirkland & Ellis

Jin has worked on the following cases- Representing Pfizer, Warner-Lambert and Viatris in the “most complex follow-on damages inquiry ever heard before the Patents Court” against the Department of Health, NHS bodies and numerous generic companies arising from cross-undertakings in damages given during the pendency of substantive patent proceedings covering the blockbuster medicine Lyrica® (pregabalin) for treating pain:[2021] EWHC 2182;[2023] EWCA Civ 166; etc. Jin also represented Pfizer and Warner-Lambert in the underlying second medical use patent proceedings:[2018] UKSC 56; etc- Representing British American Tobacco in a series of UK proceedings against Philip Morris, and coordinating proceedings in Europe and beyond, on patents concerning potentially reduced-risk products including heated tobacco, vaping, and modern oral products:[2020] EWHC 1594;[2022] EWHC 1284;[2022] EWCA Civ 1638;[2023] EWHC 854; etc- Representing Astellas and The Regents of the University of California against generic companies on patents covering the blockbuster medicine Xtandi® (enzalutamide) for treating prostate cancer- Represented Regeneron against Kymab on patents covering a transgenic mouse platform for antibody discovery:[2020] UKSC 27- Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief- Advised various global biopharmaceutical and healthcare companies on patents and SPCs covering a well-known biologic medicine for treating multiple types of cancer; small molecule medicines for treating leukaemia and kidney cancer; a well-known biologic medicine for treating eye diseases- Advised Adaptive Spectrum and Signal Alignment Inc (ASSIA) on interpretation of a patent licence clause concerning Digital Subscriber Line (DSL) technology- Represented Ilford Imaging against Harman Technology in declaratory proceedings concerning a trade mark licence agreement.